Platelet lipid composition and platelet aggregation in human liver disease

Area of Science:

• Hematology
• Lipid Metabolism
• Hepatology

Background:

• Abnormal plasma lipoproteins in liver disease elevate erythrocyte cholesterol and cholesterol/phospholipid ratio.
• This study investigates if platelets in liver disease patients share similar lipid alterations and impaired aggregation.

Purpose of the Study:

• To determine if platelet cholesterol/phospholipid ratio is increased in liver disease patients.
• To assess the impact of altered platelet lipid composition on platelet aggregation.
• To identify the specific lipid changes responsible for aggregation abnormalities.

Main Methods:

• Measured platelet aggregation induced by adrenaline and adenosine diphosphate (ADP) in 34 liver disease patients and 20 controls.
• Analyzed platelet lipid composition, including cholesterol, phospholipid, lecithin/sphingomyelin ratio, and fatty acid profiles.
• Conducted cross-incubation and hemostasis studies to rule out plasma inhibitory factors.

Main Results:

• Platelet cholesterol/phospholipid ratio was 13% higher in patients, correlating with erythrocyte ratios.
• Platelet aggregation was reduced in most patients, inversely correlating with the cholesterol/phospholipid ratio.
• Abnormalities in phospholipid (increased lecithin/sphingomyelin) and fatty acid (decreased arachidonic acid) composition were observed, inversely and positively correlating with aggregation, respectively.

Conclusions:

• Reduced platelet aggregation in liver disease is an intrinsic platelet defect, not due to plasma factors.
• Altered phospholipid and fatty acid profiles, particularly reduced arachidonic acid, override the effect of increased cholesterol, leading to impaired aggregation.
• Decreased arachidonic acid availability may limit prostaglandin and thromboxane production, explaining reduced platelet aggregation in liver disease.